Roche, Isis Pharmaceuticals to Develop Huntington's Disease Treatments

Pharmaceutical firm Roche (NASDAQOTH: RHHBY  ) and biotech company Isis Pharmaceuticals (NASDAQ: ISIS  ) have agreed to a partnership to develop treatments for Huntington's disease. The two companies, which announced the agreement in a press statement on Isis's site, will look to combine technologies and expertise in order to discover and bring drugs to market.

Roche will make a $30 million payment up front to Isis, part of a total payment schedule that could ramp up to $362 million in all if the development hits certain milestones. Roche can license any drugs Isis discovers through the first phase 1 trial's completion. That option would leave Roche in charge of global development for a drug candidate, as well as navigating global regulatory hurdles and commercialization.

Isis's lead drug candidate for the disease and Roche's "brain shuttle" technology will both be explored as viable therapies for Huntington's. Shafique Virani, Roche Partnering's global head of neuroscience, cardiovascular, and metabolism, explained the move in the statement: "This dual track development program ensures whichever candidate compound proves to be most promising -- Isis' lead target or Roche's brain shuttle version -- can be taken forward to pivotal clinical trials."

Huntington's disease currently has no effective treatment or cure, and the genetically inherited brain disorder eventually leads to patient death via complications. Current treatment options involve fighting or slowing symptoms of the disease, according to Isis' statement.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 08, 2013, at 6:34 PM, Ostrowsr wrote:

    And it's not just this agreement. ISIS has many agreements and many drugs in their own pipeline. Something like 0.5 Billion in cash. The risk is decreasing at a rapid rate for this company.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2352208, ~/Articles/ArticleHandler.aspx, 8/22/2014 11:42:47 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement